Press release
Biosimilar Monoclonal Antibodies Global Market Size, Share Analysis And Trends By 2033
Biosimilar Monoclonal Antibodies Global Market Size
According to The Business Research Company's, The biosimilar monoclonal antibodies market size has grown rapidly in recent years. It will grow from $8.04 billion in 2023 to $9.25 billion in 2024 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to patent expirations, growing awareness of biosimilars, government initiatives, increasing investment from pharmaceutical companies, growing acceptance of biosimilars by clinicians and patients.
The biosimilar monoclonal antibodies market size is expected to see rapidly grown in the next few years. It will grow to $12.79 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to rising biologic expenditure, biosimilar portfolio expansion, personalization of biosimilar therapy, increasing public interest in biosimilars. Major trends in the forecast period include therapeutic expansion, personalized biosimilars, collaborations and partnerships, biosimilar autoinjectors and devices, biobetters.
Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodie-global-market-report
Market Drivers and Trends:
The prevalence of chronic diseases is expected to drive the biosimilar monoclonal antibodies market. Biosimilar monoclonal antibodies are used to treat chronic diseases such as cancer, autoimmune diseases, and rheumatoid arthritis. In cancer treatment, biosimilars of monoclonal antibodies such as trastuzumab, bevacizumab, and rituximab are used. Moreover, the incidence of cancer is increasing year by year. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, it is projected that by the year 2050, the number of individuals aged 50 years and older who have at least one chronic illness will surge by 99.5%, rising from 71.522 million in 2020 to 142.66 million. Therefore, the prevalence of chronic diseases is expected to drive the growth of the biosimilar monoclonal antibodies market.
For instance, in July 2021, Abzena, a US-based partner research organization for biologics and bioconjugates, partnered with BioXpress Therapeutics to support biosimilar development for third-party customers. The collaboration aims to provide biosimilar medication manufacturers with an integrated approach to biosimilars that includes design advice, cell line and process development, and clinical and commercial GMP manufacturing. This collaboration enables the biosimilars sector to shorten drug development times. The strengths of BioXpress Therapeutics and Abzena are complementary, and this collaboration provides a flexible and innovative strategy from small-scale biosimilar development to large-scale manufacturing.
Key Benefits for Stakeholders:
• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=3412&type=smp
Major Key Players of the Market:
Pfizer Inc.; Novartis AG; AbbVie Inc.; Coherus BioSciences; Biocon Limited; Amgen Inc.; Boehringer Ingelheim International GmbH; Celltrion Inc.; BioXpress Therapeutics SA; Intas Pharmaceuticals Limited; Genor BioPharma Co. Ltd.; BIOCAD; Dr. Reddy's Laboratories Ltd.; 3SBio Inc.; Reliance Life Sciences; Hisun Pharmaceuticals; Celgen Biopharmaceuticals; Torrent Pharmaceuticals Ltd.; Cadila Healthcare Ltd.; Shanghai Henlius Biotech Inc.; Teva Pharmaceutical Industries Ltd.; Alvotech; Xentria Inc.; Lazuline Biotech Private Limited; Epygen Biotech Pvt Ltd.; Mabpharm Limitied; Qilu Pharmaceutical Co. Ltd.; Chiatai Tianqing Pharmaceutical Group Co. Ltd.; YL Biologics Ltd.; Aprogen Biologics; UNDBIO Co Ltd.; Samsung Bioepis Co. Ltd.; ISU Abxis Corp.; Bio-Rad Laboratories Inc.
Biosimilar Monoclonal Antibodies Market 2024 Key Insights:
• The biosimilar monoclonal antibodies market size will grow to $12.79 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%.
• Rising Prevalence Of Chronic Diseases Fuels Growth In The Biosimilar Monoclonal Antibodies Market
• Abzena And Bioxpress Therapeutics Forge Strategic Partnership To Accelerate Biosimilar Development
• North America was the largest region in the biosimilar monoclonal antibodies market in 2023
We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/Customise?id=3412&type=smp
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biosimilar Monoclonal Antibodies Global Market Size, Share Analysis And Trends By 2033 here
News-ID: 3754498 • Views: …
More Releases from The Business research company
Rising Incidence of Dental Disorders Sparks Growth in the Tooth-Filling Material …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Tooth Filling Materials Market Through 2025?
In the past few years, the market size for tooth filling materials has experienced robust growth. Projected to rise from $1.82 billion in 2024 to $1.92 billion in 2025, it's set to journey at a compound…
2025-2034 Stress Tests Equipment Market Outlook: Key Drivers, Emerging Challenge …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Stress Tests Equipment Industry Market Size Be by 2025?
In recent years, the market for stress test equipment has seen robust growth. From a value of $2.99 billion in 2024, it is projected to increase to $3.19 billion in 2025, reflecting a compound annual growth rate…
2025 Positron Emission Tomography (PET) Scanners Industry Trends Report: Long-Te …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Positron Emission Tomography (PET) Scanners Market Size By 2025?
The market size for positron emission tomography (pet) scanners has been witnessing a steady increment in the past years. The market is expected to escalate from $1.51 billion in 2024 to $1.58 billion in 2025, registering…
Strategic Forecast for the Ostomy Devices Industry: Market Outlook 2025-2034
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Ostomy Devices Market Size Growth Forecast: What to Expect by 2025?
In the past few years, the ostomy devices market has been consistently expanding. Projections show an increase from $2.8 billion in 2024 to $2.9 billion in 2025, maintaining a compound annual growth rate (CAGR) of 3.9%. The significant…
More Releases for Biosimilar
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
Get…
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02…
Infliximab Biosimilar Insight, 2023 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2023" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
